Maple syrup urine disease, type 2: Clinical Trials

5 trials for Maple syrup urine disease, type 2, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 2 unknown, 1 active not recruiting. 4 Not applicable.

By phase and status

PhaseTrialsStatus
Not applicable4Completed 2, Unknown 2

Follow Maple syrup urine disease, type 2: new trials by email Literature Review of Maple syrup urine disease, type 2 trials Research Report on Maple syrup urine disease, type 2

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Smartphone Application of "Family Connections" to Relatives of People With Borderline Personality Disorder.
Family Connections program - Relatives
Not applicableUnknownUniversitat Jaume I1162022-09-012022-03-04
"Family Connections": a Program for Relatives of People With Borderline Personality Disorder
Family Connections, Treatment As Usual - Relatives
Not applicableUnknownUniversitat Jaume I1242019-11-152020-05-05
Early Check: Expanded Screening in Newborns
Confirmatory Testing - Spinal Muscular Atrophy, Fragile X Syndrome
Active not recruitingRTI International300002018-10-152026-07-01
Magnetic Seizure Therapy for the Treatment of Borderline Personality Disorder
MagPro MST with Cool TwinCoil, DBT - Borderline Personality Disorder
Not applicableCompletedCentre for Addiction and Mental Health272017-10-172025-02-13
Adapting Dialectical Behavior Therapy for Children in Residential Care
DBT for children, Enhanced Supportive-Educational therapy - Childhood Aggression
Not applicableCompletedWeill Medical College of Cornell University472011-04-012018-07-23

Narrower conditions

Borderline Personality Disorder (3)  ·  3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency (1)  ·  3-Hydroxyacyl-CoA Dehydrogenase Deficiency (1)  ·  3-methylcrotonyl CoA carboxylase 1 deficiency (1)  ·  3-methylcrotonyl CoA carboxylase 2 deficiency (1)  ·  Acidemia, isovaleric (1)  ·  Acrodermatitis enteropathica (1)  ·  Adenine phosphoribosyltransferase deficiency (1)  ·  Adrenal hyperplasia, congenital, type 5 (1)  ·  Adrenocorticotropic hormone deficiency (1)  ·  Amaurosis congenita of Leber, type 2 (1)  ·  Anemia, Sickle Cell (1)  ·  Angelman Syndrome (1)  ·  Aortic Stenosis, Supravalvular (1)

Broader conditions

Mental Disorders (4)  ·  Personality Disorders (3)  ·  Behavior (2)  ·  Abnormalities, Multiple (1)  ·  Albinism (1)  ·  Albinism, Oculocutaneous (1)  ·  Amino Acid Metabolism, Inborn Errors (1)  ·  Anemia (1)  ·  Anemia, Hemolytic (1)  ·  Anemia, Hemolytic, Congenital (1)  ·  Aortic Valve Disease (1)  ·  Aortic Valve Stenosis (1)  ·  Arrhythmias, Cardiac (1)  ·  Avitaminosis (1)  ·  Basal Ganglia Diseases (1)

Interventions

Dialectical Behavior Therapy (1)  ·  Therapeutics (1)

Sponsors

Universitat Jaume I (2)  ·  Centre for Addiction and Mental Health (1)  ·  RTI International (1)  ·  Weill Medical College of Cornell University (1)

Countries

Spain (2)  ·  United States (2)  ·  Canada (1)

Top investigators

Cristina Botella Arbona, Dr (1)  ·  Curt Scharfe, MD, PhD (1)  ·  Daniel Blumberger, MD (1)  ·  Francheska Perepletchikova, Ph.D. (1)

Results publications

PMID 10668619, PMID 14979218, PMID 16013747, PMID 17257517, PMID 19590999, PMID 28861273, PMID 31315600, PMID 32539740, PMID 35142618, PMID 36710828